secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001689375-26-000003
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada reports ~$296M cash, completes DMD cohort 1, expands pipeline into ocular disease with ENTR-801
--------------------------------------------------------------------------------

- Preliminary cash, cash equivalents and marketable securities of ~$296M as of Dec 31, 2025; cash runway into Q3 2027.
- Completed dosing of Cohort 1 in global Phase 1/2 MAD study of ENTR-601-44 (exon 44 skipping) for DMD.
- On track to report ELEVATE-44-201 data from first cohort in Q2 2026; ELEVATE-45-201 data in mid-2026.
- Received UK MHRA authorization for Phase 1/2 ENTR-601-50; expect global initiation by end 2026 and regulatory apps for ENTR-601-51 in 2026.
- Expanded into ocular diseases: selected ENTR-801 (Usher syndrome type 2A) as first candidate; expects second candidate in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937526000003/0001689375-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937526000003/trda-20260108.htm
  HTML page:      https://secwatch.observer/filing/0001689375-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer